phase
random
doubleblind
placebocontrol
parallel
studi
recruit
hct
recipi
year
age
center
countri
supplement
materi
appendix
patient
present
time
posthct
upper
lower
respiratori
tract
rsv
infect
document
day
start
studi
treatment
evid
new
abnorm
chest
xray
obtain
hour
screen
elig
inclus
lower
respiratori
tract
involv
could
document
induc
sputum
bronchoalveolar
lavag
lung
biopsi
spontan
sputum
patient
document
concurr
lrti
respiratori
virus
exclud
full
elig
criteria
provid
supplement
method
studi
follow
intern
confer
harmonis
good
clinic
practic
guidelin
principl
declar
helsinki
approv
local
ethic
committe
written
inform
consent
obtain
patient
legal
respons
repres
data
monitor
committe
activ
chang
studi
protocol
describ
supplement
method
trial
regist
clinicaltrialsgov
eudract
enrol
began
patient
randomli
assign
receiv
presatovir
placebo
stratifi
central
supplement
oxygen
use
none
lmin
vs
lmin
ribavirin
use
prescrib
random
rout
administr
current
rsv
infect
random
schedul
use
permut
block
alloc
conceal
use
presatovir
placebo
tablet
ident
appear
studi
treatment
assign
inform
provid
interact
web
respons
system
bracket
global
wayn
pa
usa
patient
studi
staff
sponsor
mask
studi
treatment
patient
receiv
presatovir
mg
mg
tablet
placebo
oral
via
nasogastr
tube
everi
day
hour
studi
visit
day
follow
studi
day
patient
rsvposit
local
molecular
test
day
could
particip
option
extend
weekli
followup
day
detail
schedul
studi
assess
procedur
provid
supplement
tabl
virolog
assess
bilater
intranas
sampl
obtain
use
midturbin
adult
flock
swab
copan
diagnost
murrieta
ca
usa
studi
visit
sampl
analyz
use
revers
transcript
quantit
polymeras
chain
reaction
rtqpcr
determin
rsv
viral
load
rsv
sequenc
f
gene
evalu
develop
resist
multiplex
assay
identifi
coinfect
nasal
sampl
analyz
central
laboratori
detail
provid
supplement
method
antibodi
titer
pharmacokinet
method
describ
supplement
method
clinic
assess
includ
vital
sign
weight
oxygen
satur
puls
oximetri
laboratori
safeti
assess
includ
complet
blood
count
serum
electrolyt
liver
enzym
measur
patient
observ
without
oxygen
supplement
studi
visit
lowest
oxygen
satur
observ
record
cardiac
safeti
assess
via
local
electrocardiogram
troponin
test
day
addit
safeti
assess
includ
evalu
advers
event
ae
document
concomit
medic
hospit
rehospit
intens
care
unit
care
invas
noninvas
mechan
ventil
supplement
oxygen
use
lmin
primari
endpoint
timeweight
averag
chang
nasal
rsv
viral
load
measur
rtqpcr
copiesml
day
day
key
secondari
endpoint
number
supplement
oxygenfre
day
proport
patient
develop
respiratori
failur
requir
invas
noninvas
mechan
ventil
allcaus
mortal
day
prespecifi
exploratori
endpoint
describ
supplement
method
safeti
assess
ae
clinic
laboratori
paramet
assum
timeweight
averag
chang
standard
deviat
rsv
viral
load
day
day
copiesml
placebotr
patient
patient
per
treatment
group
plan
provid
approxim
power
detect
decreas
primari
endpoint
patient
receiv
presatovir
rel
placebo
use
estim
patient
would
evalu
plan
enrol
patient
safeti
popul
includ
patient
receiv
dose
studi
drug
efficaci
popul
includ
safeti
popul
patient
quantifi
rsv
viral
load
day
primari
secondari
efficaci
endpoint
analyz
efficaci
popul
post
hoc
subgroup
defin
supplement
oxygen
use
ribavirin
use
durat
rsv
symptom
graftvshost
diseas
gvhd
lymphocyt
count
time
hct
rsv
infect
day
primari
analysi
test
superior
presatovir
vs
placebo
use
parametr
analysi
covari
use
baselin
viral
load
random
stratif
factor
covari
supplement
method
number
supplement
oxygenfre
day
analyz
use
neg
binomi
model
stratif
factor
covari
offset
paramet
account
onstudi
durat
patient
die
prior
day
receiv
supplement
oxygen
day
studi
period
assign
valu
supplement
oxygenfre
day
proport
patient
develop
respiratori
failur
caus
requir
invas
noninvas
mechan
ventil
day
allcaus
mortal
day
analyz
use
cochranmantelhaenszel
test
adjust
stratif
factor
exact
confid
interv
ci
base
clopperpearson
method
treatment
group
number
event
small
fisher
exact
test
use
sequenti
test
procedur
use
control
type
error
rate
across
primari
secondari
endpoint
januari
march
patient
screen
elig
exclud
mostli
due
lack
new
radiograph
abnorm
inabl
confirm
lower
respiratori
tract
rsv
infect
figur
sixti
patient
random
assign
presatovir
placebo
patient
random
presatovir
withdrew
consent
receiv
studi
drug
notabl
protocol
deviat
describ
supplement
result
patient
demograph
baselin
characterist
gener
balanc
studi
group
tabl
overal
major
patient
underw
allogen
hct
chronic
acut
gvhd
start
studi
treatment
patient
hospit
median
day
rang
day
twentyon
patient
requir
lmin
oxygen
supplement
patient
prescrib
ribavirin
formul
rsv
lrti
confirm
induc
sputum
patient
bronchoalveolar
lavag
patient
median
time
onset
rsv
infect
symptom
start
studi
treatment
day
rang
day
infect
due
rsv
patient
rsv
b
patient
patient
presatovir
placebo
miss
day
rsv
viral
load
data
exclud
efficaci
popul
n
median
intranas
rsv
viral
load
day
copiesml
rang
copiesml
nine
patient
presatovir
placebo
prematur
discontinu
studi
treatment
patient
discontinu
studi
particip
day
presatovir
placebo
figur
twentyseven
patient
presatovir
group
patient
placebo
group
complet
treatment
day
figur
figur
show
median
absolut
rsv
viral
load
chang
baselin
studi
visit
despit
adequ
plasma
concentr
supplement
result
supplement
tabl
presatovir
treatment
significantli
reduc
timeweight
averag
chang
rsv
viral
load
day
day
copiesml
versu
copiesml
treatment
differ
copiesml
ci
p
compar
placebo
tabl
studi
period
presatovirtr
patient
placebotr
patient
requir
supplement
oxygen
median
rang
number
supplement
oxygenfre
day
similar
presatovirtr
day
placebotr
day
patient
p
tabl
three
presatovirtr
patient
placebotr
patient
develop
respiratori
failur
requir
mechan
ventil
studi
day
p
presatovirtr
patient
placebotr
patient
die
day
p
tabl
death
due
respiratori
failur
exploratori
efficaci
outcom
describ
supplement
result
primari
secondari
efficaci
endpoint
differ
appreci
patient
treat
presatovir
rel
placebo
subgroup
defin
absolut
lymphocyt
count
day
presenc
gvhd
time
onset
rsv
symptom
studi
treatment
time
rsv
infect
hct
supplement
tabl
option
extend
viral
monitor
serolog
respons
rsv
infect
present
supplement
result
sequenc
rsv
f
gene
detect
postbaselin
amino
acid
substitut
resistanceassoci
posit
presatovirtr
patient
placebotr
patient
substitut
detect
median
rang
day
start
treatment
supplement
tabl
twentyfour
presatovirtr
patient
placebotr
patient
experienc
ae
wherea
presatovirtr
patient
placebotr
patient
experienc
seriou
ae
sae
advers
event
occur
presatovirtr
patient
placebotr
patient
individu
ae
occur
presatovirtr
patient
tabl
numer
frequent
ae
patient
treat
presatovir
versu
placebo
pneumonia
increas
alanin
aminotransferas
hypokalemia
nausea
acut
sinus
epistaxi
patient
increas
aspart
aminotransferas
dri
mouth
increas
alkalin
phosphatas
patient
tabl
except
sae
pneumonia
presatovirtr
patient
grade
ae
sae
occur
patient
numer
less
frequent
overal
patient
treat
presatovir
versu
placebo
supplement
tabl
signific
imbal
electrocardiogram
troponin
result
studi
patient
treat
presatovir
patient
treat
placebo
die
studi
period
death
due
respiratori
failur
progress
acut
leukemia
anoth
patient
receiv
placebo
die
day
respiratori
failur
invas
fusariosi
first
placebocontrol
clinic
trial
knowledg
evalu
treatment
rsv
lrti
new
antivir
agent
hct
recipi
presatovir
favor
safeti
profil
well
toler
decreas
timeweight
averag
chang
nasal
rsv
viral
load
day
day
number
day
supplement
oxygen
use
frequenc
respiratori
failur
mortal
rel
placebo
contrast
presatovir
treatment
significantli
reduc
viral
load
clinic
sign
symptom
experiment
rsv
infect
healthi
volunt
treat
upon
detect
rsv
replic
potenti
explan
discrep
import
implic
design
clinic
trial
evalu
antivir
treatment
rsv
infect
hct
recipi
patient
popul
past
year
treatment
fusion
inhibitor
nucleosid
polymeras
inhibitor
significantli
reduc
rsv
viral
load
sign
symptom
challeng
studi
healthi
human
volunt
howev
clinic
trial
presatovir
conduct
multipl
differ
patient
popul
includ
studi
companion
urti
studi
chemali
et
al
issu
indic
difficulti
remain
translat
challeng
studi
result
success
clinic
trial
patient
natur
infect
one
partial
explan
challeng
model
inconsist
represent
natur
infect
set
challeng
studi
volunt
inocul
intranas
rsv
monitor
nasal
rsv
replic
twicedaili
nasal
wash
immedi
evalu
molecular
assay
rsv
antivir
treatment
initi
hour
rsv
detect
gener
sever
day
peak
viral
load
prior
manifest
signific
clinic
sign
symptom
present
studi
patient
natur
acquir
rsv
lrti
receiv
presatovir
later
diseas
cours
compar
challeng
studi
subject
median
rang
day
symptom
onset
delay
also
observ
urti
trial
median
rang
day
studi
presatovir
natur
rsv
infect
clinic
sign
symptom
tend
correl
nasal
viral
load
patient
presum
present
near
like
peak
nasal
viral
load
potenti
beyond
therapeut
window
presatovir
even
immunocompromis
patient
host
immunemedi
clearanc
viru
stage
may
also
mask
treatmentinduc
reduct
viral
load
thu
treatment
delay
may
explain
lack
presatovir
efficaci
current
studi
mechan
action
presatovir
may
also
limit
efficaci
studi
rsv
capabl
celltocel
spread
inhibit
viral
fusion
may
halt
propag
establish
infect
along
respiratori
tract
therefor
fusion
inhibitor
presatovir
may
need
administ
wherea
viruscel
fusion
still
repres
main
mode
viral
spread
appreci
reduc
nasal
viral
load
emerg
f
gene
protein
amino
acid
substitut
associ
fusion
inhibitor
resist
also
rel
frequent
immunocompromis
popul
polymeras
inhibitor
termin
intracellular
rsv
replic
may
wider
therapeut
window
compar
fusion
inhibitor
howev
polymeras
inhibitor
demonstr
clinic
efficaci
natur
infect
set
date
furthermor
nasal
viral
load
question
primari
endpoint
proofofconcept
studi
natur
infect
patient
lrti
upper
respiratori
tract
sampl
although
conveni
obtain
may
reflect
viral
activ
lower
respiratori
tract
particularli
immunocompromis
patient
altern
approach
need
noninvas
measur
viral
diseas
dynam
antivir
activ
lower
airway
alveolar
tissu
find
trial
call
question
whether
appear
new
radiolog
opac
document
rsv
upper
lower
respiratori
tract
accur
classifi
patient
rsv
infect
approach
may
satisfactori
retrospect
studi
inadequ
enrol
criterion
prospect
clinic
trial
radiograph
find
adult
rsv
lrti
confirm
lower
respiratori
tract
specimen
well
character
radiograph
abnorm
patient
may
caus
virus
bacteria
immunocompromis
even
noninfecti
process
rsv
chiefli
affect
airway
epithelium
rsv
lrti
could
manifest
without
radiograph
find
present
lower
airway
symptom
eg
wheez
obstruct
spirometri
pattern
furthermor
degre
lung
injuri
patient
rsv
lrti
may
revers
antivir
treatment
alon
issu
need
consid
futur
clinic
trial
lack
clinic
benefit
studi
may
also
relat
select
clinic
endpoint
occur
lowerthananticip
rate
decreas
power
detect
treatment
effect
although
subject
enrol
current
studi
met
waghmar
et
al
criteria
proven
probabl
lrti
median
number
supplement
oxygenfre
day
day
much
higher
day
presatovirtr
placebotr
patient
respect
vs
day
fewer
patient
requir
lmin
supplement
oxygen
baselin
versu
rel
patient
present
develop
lrti
waghmar
studi
furthermor
lymphopenia
major
risk
factor
rsv
infect
subsequ
poor
outcom
hct
recipi
patient
avail
data
current
studi
lymphopen
baselin
possibl
rsv
infect
occur
rel
late
hct
median
vs
day
waghmar
studi
differ
could
due
limit
enrol
patient
perceiv
fragil
requir
lower
respiratori
sampl
confirm
rsv
lrti
enrich
studi
popul
immunosuppress
patient
consid
futur
clinic
trial
therapi
rsv
infect
hct
recipi
summari
presatovir
treatment
gener
well
toler
hct
recipi
natur
acquir
rsv
lrti
achiev
virolog
clinic
endpoint
tendenc
adult
natur
acquir
rsv
infect
seek
treatment
sever
day
symptom
treatment
window
may
close
fusion
inhibitor
particular
challeng
clinic
trial
rsvspecif
antivir
therapi
numer
lower
rate
pulmonari
complic
presatovir
urti
trial
suggest
earli
treatment
lrti
develop
key
success
futur
studi
